Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.67 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.53 |
| ▸ | HTR1A | P08908 | 11/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | HTR1D | P28221 | 8/20 | 0.50 |
| ▸ | HTR1B | P28222 | 8/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122500 | 0.90 | PARP1 (0.82) | PARP1HTR1ADRD2HTR2AHTR1D | |
| SCHEMBL532506 | 0.80 | PARP1 (1.00) | PARP1HTR1ADRD2HTR2ASIGMAR1 | |
| SCHEMBL531687 | 0.78 | DRD2 (0.66) | PARP1NR3C2HTR1ADRD2HTR2A | |
| SCHEMBL2304302 | 0.76 | HTR1D (0.68) | HTR1ADRD2HTR2AHTR1DHTR1B | |
| SCHEMBL3777754 | 0.75 | HTR1A (0.58) | PARP1NR3C2HTR1ADRD2HTR2A | |
| SCHEMBL12346145 | 0.75 | HTR1A (0.67) | PARP1HTR1ADRD2HTR2AHTR1D | |
| SCHEMBL11002313 | 0.73 | PARP1 (0.77) | PARP1NR3C2HTR1ADRD2HTR1D | |
| SCHEMBL531893 | 0.72 | PARP1 (0.66) | PARP1HTR1ADRD2HTR2A | |
| SCHEMBL8785277 | 0.72 | HTR1A (0.64) | HTR1ADRD2HTR2AHTR1DHTR1B | |
| SCHEMBL532419 | 0.72 | PARP1 (0.82) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| WO-2010111626-A2 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885NR3C2 4674/4885HTR1A 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.